Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...

Shares of Teleflex Inc. TFX rallied 2.55% to $112.81 Friday, on what proved to be an all-around positive trading session for ...

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

On August 1, Teleflex will release earnings for the most recent quarter. Analysts on Wall Street expect Teleflex will release earnings per share of $3.33. Track Teleflex stock price in real-time on ...

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...

Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest ...

We recently made a list of Piper Sandler’s Top Technical Stock Picks: 20 Best Stocks. In this piece, we will look at where Teleflex Incorporated (NYSE:TFX) ranks among the list of stocks with ...

Teleflex is a medical device and instrument manufacturer with $3 billion in sales, supplying a wide range of products. The company saw strong growth in the 2010s as growth slowed down in recent years.